ST诺泰表示，报告期内，公司贯彻"时间领先、技术领先"的经营理念，各项主营业务有序开展，净利 润实现稳健增长。 北京商报讯（记者 丁宁）10月10日晚间，ST诺泰（688076）发布第三季度业绩预告显示，公司预计第 三季度实现归属净利润为1.3亿元到1.4亿元，与上年同期（法定披露数据）相比，将增加691.45万元到 1691.45万元，同比增加5.62%到13.74%。 ...

Core Viewpoint - ST诺泰 (688076) expects to achieve a net profit attributable to shareholders of the parent company between 130 million to 140 million yuan in the third quarter of 2025, representing a year-on-year increase of 5.62% to 13.74% [1] Group 1 - The company reports that its main business operations are progressing smoothly during the reporting period [1] - The net profit is expected to show steady growth [1]

智通财经APP讯，ST诺泰(688076.SH)发布第三季度业绩预告，预计2025年第三季度实现归属于母公司 所有者的净利润1.3亿元至1.4亿元，同比增加5.62%到13.74%。报告期内，公司贯彻"时间领先、技术领 先"的经营理念，各项主营业务有序开展，净利润实现稳健增长。 ...

Core Viewpoint - ST Nuotai (688076.SH) expects a net profit attributable to shareholders of the parent company to be between 130 million to 140 million yuan in Q3 2025, representing a year-on-year increase of 5.62% to 13.74% [1] - The company also anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 130 million to 140 million yuan, with a year-on-year increase of 3.76% to 11.74% [1] Financial Performance - The projected net profit for Q3 2025 is estimated to be between 130 million to 140 million yuan [1] - The expected year-on-year growth rates for net profit are between 5.62% to 13.74% [1] - The anticipated net profit, excluding non-recurring items, is also projected to be between 130 million to 140 million yuan, with growth rates of 3.76% to 11.74% [1] Business Strategy - The company adheres to the business philosophy of "time-leading, technology-leading," ensuring orderly development of its main businesses [1] - The implementation of this strategy has contributed to stable growth in net profit [1]

Group 1 - The core viewpoint of the article is that ST Nuotai (SH 688076) expects a net profit of 130 million to 140 million yuan for the third quarter of 2025, representing a year-on-year increase of 5.62% to 13.74% [1] - The increase in net profit is attributed to the company's implementation of the "time-leading, technology-leading" business philosophy, which has led to steady growth in its main business operations [1] - For the year 2024, ST Nuotai's revenue composition is heavily weighted towards the pharmaceutical manufacturing industry, accounting for 99.88% of total revenue, with other businesses making up only 0.12% [1] Group 2 - As of the report, ST Nuotai has a market capitalization of 12.7 billion yuan [2]

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-068 江苏诺泰澳赛诺生物制药股份有限公司 2025年第三季度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 7 月 1 日至 2025 年 9 月 30 日。 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年第三季度实现归属于母公司所有者 的净利润为 13,000 万元到 14,000 万元，与上年同期（法定披露数据）相比，将 增加 691.45 万元到 1,691.45 万元，同比增加 5.62%到 13.74%。 （2）预计 2025 年第三季度实现归属于母公司所有者的扣除非经常性损益的 净利润为 13,000 万元到 14,000 万元，与上年同期（法定披露数据）相比，将增 加 470.61 万元到 1,470.61 万元，同比增加 3.76%到 11.74%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 2024 年第三季度，公司利润 ...

Group 1 - Recent information disclosure violations have been reported by companies such as Jinsheng New Materials, *ST Aowei, and ST Nuotai, leading to significant market value loss for investors and undermining trust in the capital market's integrity [1][2] - Jinsheng New Materials received a warning letter from the Zhejiang Securities Regulatory Bureau for multiple violations, including failure to disclose related party transactions in a timely manner and mixing management with its actual controller [2] - The company has faced continuous losses, with reported revenues increasing from 243 million yuan in 2022 to 333 million yuan in 2024, but net profits showing losses of over 69 million yuan cumulatively during the same period [2] Group 2 - ST Nuotai was found to have inflated revenue by 30 million yuan through non-commercial transactions in 2021, which misled investors regarding its financial health [3][4] - The company continued to use false financial data in its convertible bond issuance documents in 2023, further misleading investors and disrupting normal financing order in the capital market [4] - Investors who purchased ST Nuotai shares between April 28, 2022, and October 23, 2024, may seek compensation for losses [4] Group 3 - *ST Aowei announced a significant downward revision of its financial forecasts, with net profit losses expected to widen from an initial estimate of 32 million to 45 million yuan to a range of 50 million to 75 million yuan [5] - The company's revenue forecast was also drastically reduced from 450 million to 520 million yuan down to 280 million to 299 million yuan [5] - Investors who bought shares between January 24, 2025, and April 21, 2025, may also pursue claims for compensation [5]

Group 1 - A new company, Wuxi Nuotai Biotechnology Co., Ltd., has been established with a registered capital of 750,000 RMB [1] - The legal representative of the company is Yu Yuxing [1] - The company's business scope includes sales of magnetic materials, research and development of new materials, manufacturing and sales of bio-based materials, and various sales of chemical products [1] Group 2 - The company is involved in the sales of medical devices, both Class I and Class II [1] - It also engages in import and export activities, including technology services, development, consulting, and promotion [1] - The company focuses on industrial enzyme preparations and bio-based material polymer technology research and development [1]

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-067 江苏诺泰澳赛诺生物制药股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 9 月 5 日 （二） 股东会召开的地点：浙江省杭州市余杭区文一西路 1378 号杭州师范大学 科技园 E 座 12 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 207 | | --- | --- | | 普通股股东人数 | 207 | | 2、出席会议的股东所持有的表决权数量 | 135,496,040 | | 普通股股东所持有表决权数量 | 135,496,040 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 42.8715 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量 ...

诺泰生物 2025 年第一次临时股东会法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 关 于 江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会 法律意见书 致：江苏诺泰澳赛诺生物制药股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受江苏诺泰澳赛诺生物制 药股份有限公司（以下简称"公司"）委托，指派律师出席公司 2025 年第一次 临时股 ...